The organization has been adding a few quills to its cap in late quarters. In December, it presented an application for the utilization of Firdapse through its accomplice in Japan. The medication treats patients with Lambert Eaton Myasthenic Condition (LEMS) and is the main supported treatment for the sickness in the U.S. LEMS is a condition that can influence the capacity of nerves to convey messages to the muscles.
In November, the U.S. patent office acknowledged two additional patent applications for Firdapse while in July, the organization got select privileges to showcase Agamree, a medication to treat an uncommon hereditary state of debilitating muscles that can be dangerous.
In September 2022, Impetus won the option to create and popularize Ruzurgi, one more medication to treat LEMS, in the U.S. what’s more, Mexico.